Hikma launches Clobazam oral suspension and Clobazam tablets

Published: 11-Dec-2018
Pharmaceutical

Hikma Pharmaceuticals has launched Clobazam oral suspension, 2.5 mg/mL, and Clobazam tablets, 10 and 20 mg, the generic equivalent to Onfi


Hikma’s Clobazam is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

According to IQVIA, US sales of Clobazam oral suspension were approximately $260 million and of Clobazam tablets were approximately $601 million in the 12 months ending September 2018.

Brian Hoffmann, President, Generics Division, said: “We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio. This will be among the first generics available on the market and we are pleased to improve patients’ access to this important medicine.”

  • Companies:
  • Hikma Pharmaceuticals
See more

You may also like

Manufacturing

Hikma establishes distribution partnership with Melinta

Read more
The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Hikma establishes distribution partnership with Melinta

The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region
Distribution

Hikma announces exclusive agreement with Sciecure Pharma for niche injectable antiviral medicine

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Drug Delivery

Hikma announces agreement with Vectura to develop generic salmeterol for the US market

Hikma is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products
Finance

Hikma to buy Boehringer Ingelheim's Roxane business for US$2.65bn in cash and stock

Will boost its presence in US generics market
Finance

Hikma completes purchase of assets of Bedford Laboratories

Strengthens position as a leading generic injectables company in the US
Drug Delivery

Hikma signs transdermal patch supply agreement with SK Chemicals of South Korea

For the first approved generic Rivastigmine transdermal patch for dementia in Alzheimer\'s disease
Subscribe now